Associação do methimazole e do ondansetron à quimioterapia com cisplatina em cães submetidos a quatro diferentes protocolos de fluidoterapia

Repetti, Cláudia Sampaio Fonseca; Daleck, Carlos Roberto

doi:10.1590/s0102-09352007000300018

Cited by 1 publication

(1 citation statement)

References 10 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The carboplatin was administered 5 minutes after gemcitabine through the same catheter at a dose of 10 mg/kg IV for 20 minutes. Before, between, and after chemotherapy administrations, 25 ml/kg/hour of 0.9% saline solution was administered as recommended for platinum-derived protocols (Repetti and Daleck, 2007). As chemotherapy-induced toxicity prophylaxis, ondansetron hydrochloride (0.5 mg/kg PO every 12 hours) was given for 6 days and starting 3 days before each chemotherapy session for all dogs.…”

Section: Chemotherapy Administrationmentioning

confidence: 99%

Clinical and Laboratory Findings in Dogs Undergoing Adjuvant Chemotherapy with Gemcitabine/Carboplatin Combination for Mammary Neoplasia

Israel¹,

Maués²,

Ferreira³

et al. 2021

WVJ

View full text Add to dashboard Cite

Adjuvant chemotherapy might be indicated in some canine mammary cancer cases due to metastatic potential. In this regard, studies to determine adverse events following chemotherapy protocols are valuable. The purpose of this prospective clinical trial was to evaluate the safety and tolerability of gemcitabine and carboplatin combination in dogs with malignant mammary tumors. For this prospective clinical trial, 21 female dogs mastectomized due to malignant mammary neoplasia underwent adjuvant chemotherapy with gemcitabine (3 mg/kg, 60-minute IV infusion) and carboplatin (10 mg/kg, 20-minute IV infusion) based protocol every 21 days for three cycles. They were monitored periodically for treatment-related adverse events by clinical and laboratory evaluations. A total of 17 (80.9%) dogs developed leukopenia, 10 (47.6%) neutropenia, and 15 (71.4%) thrombocytopenia at least once along with the three chemotherapy cycles. All these hematologic toxicities were grade 1, 2, or 3. Two (9.5%) animals had evidence of gastrointestinal toxicity; however, clinical signs were mild to moderate (grades 1 and 2). No dog had life-threatening adverse events (grade 4) or even died (grade 5) of treatment-related complications. The adjuvant chemotherapy protocol with gemcitabine and carboplatin was well-tolerated and safe in female dogs for mammary cancer treatment with self-limiting hematological and gastrointestinal adverse events.

show abstract

Section: Chemotherapy Administrationmentioning

confidence: 99%